Christopher L. Carpenter is Chief Medical Officer at Rubius Therapeutics, Inc. (RUBY). They have made 6 open-market trades across 1 company since 2019, most recently 2019-12-16.
CIK 0001746845
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RUBY | 82,843 | $14K |
Shares reported on the most recent Form 4, priced at the 2019-12-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RUBY | SELL | 2019-12-16 | 2019-12-18 | $13.48 | $647K | -32.8% | -36.9% | -73.5% |
| RUBY | SELL | 2019-09-17 | 2019-09-18 | $10.05 | $119K | -23.3% | -13.0% | +32.8% |
| RUBY | SELL | 2019-09-16 | 2019-09-18 | $10.11 | $970K | -23.3% | -13.0% | +32.8% |
| RUBY | SELL | 2019-09-16 | 2019-09-18 | $10.13 | $366K | -23.3% | -13.0% | +32.8% |
| RUBY | SELL · 10b5-1 | 2019-06-20 | 2019-06-24 | $13.93 | $3K | +11.0% | -0.3% | -27.6% |
| RUBY | SELL | 2019-06-17 | 2019-06-19 | $14.00 | $1.1M | +7.7% | +7.9% | -28.8% |
| RUBY | SELL | 2019-03-15 | 2019-03-19 | $15.84 | $760K | +11.6% | +5.1% | -11.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.